CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility

Titre officiel

CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility

Sommaire:

Il s’agit d’une étude d’observation prospective chez des patients atteints d’un cancer du poumon non à petites cellules (CPNPC) qui commencent une chimiothérapie cytotoxique ou une radiothérapie. L’étude évaluera les changements de l’ADN tumoral circulant (ADNtc) dans les jours suivant le début du traitement, ainsi que la surveillance longitudinale, afin d’évaluer la dynamique et la valeur de l’ADNtc dans les CPNPC de stade III-IV.

Description de l'essai

Primary Outcome:

  • To measure the change in quantitative ctDNA levels following the initiation of cytotoxic chemotherapy or radiation
  • To identify the timepoint after the initiation of treatment at which the quantified level of ctDNA peaks
  • To detect genetic alterations at the time point of maximal ctDNA that were not present in baseline testing
Secondary Outcome:
  • To identify the proportion of patients that do not have genetic alterations present in baseline samples but have genetic alterations detected at the timepoint of maximal quantified ctDNA
  • To determine the percentage of stage III patients with clinically relevant (targetable or prognostic), at any stage of lung cancer, ctDNA genetic alterations.
The study consists of three cohorts of patients initiating a new treatment for their NSCLC. The cohorts of (1) patients starting concurrent chemotherapy and radiation for stage III NSCLC (2) patients with advanced NSCLC starting cytotoxic chemotherapy (with or without pembrolizumab) (3) patients with advanced NSCLC starting palliative radiation therapy. This study aims to study the changes in ctDNA levels following a new treatment in lung cancer patients and to explore if the diagnostic utility of ctDNA testing is improved immediately following treatment when tumour cells are actively dying. It will also examine the changes in ctDNA levels and mutational analysis longitudinally.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer